...agonists for cancer immunotherapy. The two-year collaboration starts next month. m4 is part of the Munich Biotech...

...stream because it's a validation of their technology." Bernhard Wimmer, project and investment manager at Munich BioTech...

...5/4/04 - Yamanouchi launches Eligard in Germany M. 8/13/04 - MDG acquires the assets of Munich Biotech...

...which is in a Phase I/II trial in pancreatic cancer, through its 2004 acquisition of Munich Biotech AG...

...Hired: Uwe Michaelis as VP of research, formerly an executive board member for R&D at Munich Biotech AG...

...FSE:MDG), Martinsried, Germany Munich Biotech AG , Neuried, Germany Business: Cancer MediGene (FSE:MDG) acquired the assets of Munich Biotech...

...MediGene (FSE:MDG) acquired the assets of Munich Biotech from the company’s investors in exchange for 2 million...

...Cancer play Munich Biotech (Neuried, Germany) said it filed for insolvency last week. The company's MBT-0206 intravenous...
...Phase I testing to treat metastatic solid tumors last December. Both products are formulated with Munich Biotech's...

...remission. The compound is in Phase II for metastatic breast cancer and metastatic pancreatic cancer. Munich Biotech AG...

...patients. A control arm will be added to the trial if undisclosed milestones are met. Munich Biotech AG...